$ 185,50
Updated 09:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 1,691,380
High $ 187.35
Low $ 184.77
Open $ 186.39
ISIN
Prev close $ 186.92
# of shares 622.28M
Market cap 115,433M USD
Intraday

Market closed
Amgen Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  185.50 -1.5% Stock price decreasing -8.2% Stock price decreasing -3.8% Stock price decreasing -6.2% Stock price decreasing 1.7% Stock price increasing
Powered by TradingView

News about Amgen Inc

  • English
  • Regulatory news

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Abbott Laboratories 75.14 -0.1% Stock price decreasing 5.1% Stock price increasing 9.6% Stock price increasing 14.4% Stock price increasing 27.4% Stock price increasing 3.9% Stock price increasing
 
Bristol-Myers Squibb Company 50,13 -3.0% Stock price decreasing 0.8% Stock price increasing -5.8% Stock price decreasing -17.2% Stock price decreasing -24.0% Stock price decreasing -3.6% Stock price decreasing
 
Johnson & Johnson 135,42 -0.7% Stock price decreasing 5.1% Stock price increasing -4.6% Stock price decreasing 0.6% Stock price increasing 4.2% Stock price increasing 4.9% Stock price increasing
 
Eli Lilly and Company 122.72 0.2% Stock price increasing 4.8% Stock price increasing 9.3% Stock price increasing 16.8% Stock price increasing 59.0% Stock price increasing 6.0% Stock price increasing
 
Merck & Company Inc (new) 79.83 0.0% Stock price increasing 5.3% Stock price increasing 6.7% Stock price increasing 15.6% Stock price increasing 46.3% Stock price increasing 4.5% Stock price increasing
 
Pfizer Inc 42,14 -0.6% Stock price decreasing -0.3% Stock price decreasing -2.2% Stock price decreasing 0.2% Stock price increasing 17.9% Stock price increasing -3.5% Stock price decreasing
 
Merck Kgaa O.N. 95,74 -1.2% Stock price decreasing 5.9% Stock price increasing -0.7% Stock price decreasing 4.0% Stock price increasing 16.2% Stock price increasing 6.4% Stock price increasing
 
Novartis NAM SF 0,50 79,40 0.0% Stock price decreasing 2.0% Stock price increasing 3.9% Stock price increasing 9.5% Stock price increasing 14.5% Stock price increasing 6.7% Stock price increasing
 
Roche Hldg AG GEN 243,20 1.4% Stock price increasing 6.5% Stock price increasing 13.5% Stock price increasing 14.7% Stock price increasing 25.8% Stock price increasing 12.9% Stock price increasing
 
Glaxosmithkline PLC ORD 25P 1,524.00 -3.6% Stock price decreasing 2.2% Stock price increasing -2.6% Stock price decreasing -5.6% Stock price decreasing 17.0% Stock price increasing 2.2% Stock price increasing
 
Takeda PHARM.CO.LTD. 34.73 -2.5% Stock price decreasing -1.4% Stock price decreasing 5.2% Stock price increasing -4.2% Stock price decreasing -21.3% Stock price decreasing 20.0% Stock price increasing
 
Sanofi 72.57 -3.5% Stock price decreasing -0.8% Stock price decreasing -7.3% Stock price decreasing -3.0% Stock price decreasing 11.8% Stock price increasing -4.1% Stock price decreasing
 
Biogen Inc 321,17 -3.5% Stock price decreasing -5.2% Stock price decreasing 1.8% Stock price increasing -6.9% Stock price decreasing 12.8% Stock price increasing 6.7% Stock price increasing
 
Bayer AG NA O.N. 68,04 -0.2% Stock price decreasing 3.2% Stock price increasing 9.3% Stock price increasing -18.4% Stock price decreasing -30.9% Stock price decreasing 12.4% Stock price increasing
 
Teva Pharmaceutical Industries.. 17.25 -4.1% Stock price decreasing -8.0% Stock price decreasing -21.7% Stock price decreasing -31.5% Stock price decreasing -12.9% Stock price decreasing 11.9% Stock price increasing

Company profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Peers

Instruments Last Change  
Abbott Labor.. 75.14 -0.5% Stock price decreasing
Bristol-Myer.. 50,13 -2.3% Stock price decreasing
Johnson & Jo.. 135,42 -0.7% Stock price decreasing
Eli Lilly an.. 122.72 0.0% Stock price increasing
Merck & Comp.. 79.83 0.5% Stock price increasing
Pfizer Inc 42,14 -0.1% Stock price decreasing
Merck Kgaa O.. 95,74 -0.3% Stock price decreasing
Novartis NAM.. 79,40 -0.5% Stock price decreasing
Roche Hldg A.. 243,20 -0.1% Stock price decreasing
Glaxosmithkl.. 1,524.00 -0.9% Stock price decreasing
Takeda PHARM.. 34.73 -0.9% Stock price decreasing
0,0,0,0,0,0,0,0,0,0
Sanofi 72.57 -0.7% Stock price decreasing
Biogen Inc 321,17 0.0% Stock price unchanged
Bayer AG NA .. 68,04 0.2% Stock price increasing
Teva Pharmac.. 17.25 -0.9% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:17:51
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB6 - 2019-02-22 10:17:51 - 2019-02-22 09:17:51 - 1000 - Website: OKAY